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Abstract
Different fusion oncogenes in acute myeloid leukemia (AML) have distinct clinical and laboratory features suggesting
different modes of malignant transformation. Here we compare the in vitro effects of representatives of 4 major groups of
AML fusion oncogenes on primary human CD34+ cells. As expected from their clinical similarities, MLL-AF9 and NUP98-
HOXA9 had very similar effects in vitro. They both caused erythroid hyperplasia and a clear block in erythroid and myeloid
maturation. On the other hand, AML1-ETO and PML-RARA had only modest effects on myeloid and erythroid differentiation.
All oncogenes except PML-RARA caused a dramatic increase in long-term proliferation and self-renewal. Gene expression
profiling revealed two distinct temporal patterns of gene deregulation. Gene deregulation by MLL-AF9 and NUP98-HOXA9
peaked 3 days after transduction. In contrast, the vast majority of gene deregulation by AML1-ETO and PML-RARA occurred
within 6 hours, followed by a dramatic drop in the numbers of deregulated genes. Interestingly, the p53 inhibitor MDM2
was upregulated by AML1-ETO at 6 hours. Nutlin-3, an inhibitor of the interaction between MDM2 and p53, specifically
inhibited the proliferation and self-renewal of primary human CD34+ cells transduced with AML1-ETO, suggesting that
MDM2 upregulation plays a role in cell transformation by AML1-ETO. These data show that differences among AML fusion
oncogenes can be recapitulated in vitro using primary human CD34+ cells and that early gene expression profiling in these
cells can reveal potential drug targets in AML.
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Introduction
Acute myeloid leukemia (AML) is a group of hematopoietic
disorders characterized by uncontrolled proliferation and various
degrees of blocked differentiation. Approximately 50% of AML
patients have chromosomal rearrangements that result in the
expression of fusion oncogenes [1], the majority of which involve
genes that fall into four groups:
1) Core-binding factor (CBF) transcriptional regulators - these
fusions involve the two subunits of CBF: AML1 and CBFB. The
most common is t(8;21)(q22;q22) that fuses AML1 (RUNX1) with
ETO (RUNX1T1), resulting in expression of AML1-ETO [2].
2) Retinoic acid receptor alpha (RARA) - rearrangements of the
RARA gene result in acute promyelocytic leukemia (APL), a
subtype of AML. The most common RARA rearrangement is the
t(15:17)(q21;q22) translocation that fuses RARA to the promyelo-
cytic leukemia gene (PML) resulting in expression of PML-RARA
[3].
3) Mixed lineage leukemia (MLL) - at least 104 different
rearrangements of the MLL gene at chromosome 11q23 have been
identified and 64 different fusion partners have been molecularly
characterized [4]. The most frequent MLL gene translocation in
AML is t(9;11)(p22;q23) which results in expression of the MLL–
AF9 fusion [4,5,6].
4) Nucleoporins - two nucleoporins have been implicated in
AML: NUP214 and NUP98 [7,8,9,10]. While only a handful of
NUP214 rearrangements have been described, there are at least 24
NUP98 fusion oncogenes. The prototype of NUP98 fusions
is NUP98-HOXA9 that results from the t(7;11)(p15;p15)
translocation.
Clinical data indicate that leukemias associated with MLL and
NUP98 gene rearrangements have similar features and are
biologically distinct from those associated with CBF and RARA
gene rearrangements. The former tend to follow treatment with
topoisomerase II inhibitors, have multiple fusion partners, and
respond poorly to treatment [5,6,9,11,12,13]; whereas the latter
usually occur de novo, have one major fusion partner, and have a
favorable prognosis [1].
Numerous studies have sought to recapitulate human AML by
expressing fusion oncogenes in mouse bone marrow [14]. On the
other hand, studies of the leukemic transformation of primary
human hematopoietic cells by AML oncogenes are relatively few
[15,16,17,18,19,20,21,22,23,24] in spite of the fact that they offer
the potential to identify drug targets and to test drug candidates
[25]. In the available studies the source of cells, assays used,
culture conditions, and the extent and timing of gene expression
profiling have been variable, precluding a comparison of the
effects of different AML oncogenes.
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whether the clinical differences among the various AML
oncogenes are reflected in different modes of transformation in
vitro using primary human CD34+ cells, and whether early in vitro
gene expression profiling can shed light on mechanisms of
leukemogenesis. We compared the in vitro effects of 4 representa-
tive AML oncogenes, PML-RARA, AML1-ETO, MLL-AF9 and
NUP98-HOXA9, on the differentiation, proliferation, and self-
renewal of primary human CD34+ cells under identical
conditions. We also performed gene expression profiling in
duplicate for each oncogene over 3 time points starting 6 h after
transduction. Early gene expression profiling showed upregulation
of MDM2 that was confirmed by quantitative RT-PCR and
immunoblotting in triplicate. Treatment with the MDM2 inhibitor
nutlin-3 suppressed long-term growth and self-renewal of cells
transformed by AML1-ETO, suggesting that MDM2 is a possible
mediator and drug target in AML1-ETO leukemogenesis. Our
data suggest that early gene expression profiling in combination
with in vitro assays using primary human CD34+ cells can lead to
the discovery of potential drug targets that may not be identifiable
by other approaches.
Results
NUP98-HOXA9 and MLL-AF9 show similar effects on
differentiation that differ from those of AML1-ETO and
PML-RARA
In order to determine whether the clinical differences among
the various AML oncogenes are reflected during the in vitro
transformation of primary human cells, retroviral vectors express-
ing AML1-ETO, PML-RARA, MLL-AF9, or NUP98-HOXA9
were used to transduce human CD34+ hematopoietic progenitor/
stem cells from mobilized peripheral blood. GFP-positive cells
were sorted and protein expression was confirmed by immuno-
blotting (Fig. 1A). Cells were plated for colony-forming cell (CFC)
assays, and after 14 days, the NUP98-HOXA9 and MLL-AF9
plates looked markedly different from the others, with large
prominent erythroid colonies (Fig. 1B). PML-RARA samples
showed increased numbers of small erythroid colonies (Fig. 1B and
Table 1). AML1-ETO caused a decrease in the number of
erythroid colonies, consistent with previously published data [18].
To evaluate differentiation at the cellular level, 500-cell
differential counts from Giemsa-stained slides of cells recovered
from the CFC plates were performed. Cells were classified into
primitive, intermediate myeloid, mature myeloid, intermediate
erythroid, and mature erythroid (see Materials and Methods). The
average numbers from 3 independent experiments are shown in
Table 2 and representative fields are shown in Fig. 1B. Both
NUP98-HOXA9 and MLL-AF9 caused a marked increase in the
numbers of erythroid cells. In addition, NUP98-HOXA9 caused a
marked shift of the erythroid cells towards intermediate differen-
tiation, indicating a block in erythroid maturation. In contrast,
AML1-ETO and PML-RARA did not show a significant effect on
the numbers and maturation of erythroid cells in spite of their
effects on erythroid colony numbers. All fusion oncogenes
increased the percentage of primitive cells (blasts and promyelo-
cytes), although the difference was at the border of statistical
significance in the case of PML-RARA. On the other hand, all
oncogenes except AML1-ETO caused an increase in the
percentage of intermediate myeloid cells and a decrease in mature
myeloid cells, consistent with a block in myeloid maturation.
Differentiation was further assessed by flow cytometry. For
myeloid differentiation, CD11b expression on CD33+ myeloid
cells was compared to the control sample (Fig. 1C). NUP98-
HOXA9, MLL-AF9, and to a lesser extent PML-RARA
decreased the expression of CD11b, whereas AML1-ETO had
no obvious effect on CD11b expression. For flow cytometric
analysis of erythroid differentiation, erythroid cells (CD235a+)
were gated and the level of CD71 expression was compared to the
control sample (Fig. 1D). Both NUP98-HOXA9 and MLL-AF9
caused an increase in CD71 expression on erythroid cells
indicating a block in terminal erythroid differentiation; in contrast,
neither AML1-ETO nor PML-RARA caused a block in erythroid
differentiation.
In summary, NUP98-HOXA9 and MLL-AF9 showed similar
effects on differentiation including a block of both myeloid and
erythroid maturation and an increase in erythroid cells. In
contrast, PML-RARA and AML1-ETO altered the numbers of
erythroid colonies but had no significant effects on the maturation
and numbers of erythroid cells, and had limited effects on myeloid
differentiation.
Fusion oncogenes, except PML-RARA, induce long-term
proliferation and self-renewal of primary human CD34+
cells
The effects of the fusion oncogenes on the proliferation of
primary human CD34+ cells were measured by long-term in vitro
culture. Sorted primary human CD34+ cells transduced with
control, AML1-ETO, PML-RARA, MLL-AF9, or NUP98-
HOXA9 retrovirus were continuously cultured in liquid media
with a cytokine cocktail and subjected to periodic cell counting
and feeding as previously described [20]. The typical growth
pattern, which was reproducible in three independent experi-
ments, is shown in Fig. 2A. With the exception of PML-RARA,
the fusion oncogenes increased cell numbers several orders of
magnitude over the control samples during almost 4 months of
continuous culture.
To assess the numbers of self-renewing cells, the long-term
culture-initiating cell (LTC-IC) assay [26] was performed. Again
all the fusion oncogenes except PML-RARA induced a marked
increase in LTC-IC numbers compared to control (Fig. 2B and
2C).
Gene expression profiling shows 2 distinct temporal
patterns of gene deregulation by AML oncogenes
In order to explore the molecular basis behind the in vitro
biological findings, gene expression profiling was performed at 3
time points: 6 h, 3 d, and 8 d. For the 3 d and 8 d time points, the
oncogenes were retrovirally expressed in primary human CD34+
cells as described above, with cells transduced with empty
retroviral vector as controls. As retroviral transduction requires
days, for the 6 h time point the oncogenes were expressed from a
pTracer-CMV/Bsd plasmid using nucleofection. Cells nucleo-
fected with empty pTracer-CMV/Bsd vector were used as a
control. At all time points, fold changes in gene expression levels
were obtained for each oncogene compared to empty vector
control as described in Materials and Methods. The entire
experiment was performed twice, and only genes that showed a
2-fold or more difference from control in both experiments were
considered deregulated (Tables S1, S2, S3, S4, S5, S6, S7, S8, S9,
S10, S11 and S12). AML1-ETO and PML-RARA deregulated
large numbers of genes within 6 h of introduction into cells and
the number of deregulated genes fell sharply thereafter (Fig. 3).
This is consistent with the fact that AML1-ETO and PML-RARA
are aberrant transcription factors with direct effects on gene
transcription. Notably, there was a preponderance of downregu-
lated genes in both cases at 6 h: AML1-ETO upregulated 996
AML Oncogenes in CD34+ Cells
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271 genes and downregulated 675 genes (Tables S1, S2, S3, S4, S5
and S6). This is consistent with data indicating that AML1-ETO
and PML-RARA can act as transcriptional repressors [3,27]. In
contrast, gene deregulation by NUP98-HOXA9 and MLL-AF9
peaked at 3 days after introduction of the oncogene with a
preponderance of upregulated genes: MLL-AF9 upregulated 244
genes and downregulated 151 genes; NUP98-HOXA9 upregu-
lated 419 genes and downregulated 28 genes (Fig. 3 and Tables
S7, S8, S9, S10, S11 and S12). The later peak of gene deregulation
by NUP98-HOXA9 and MLL-AF9 suggests that some of the
effects of NUP98 and MLL fusions on gene expression may not be
due to direct transcriptional modulation. The similar time course
of gene deregulation by NUP98-HOXA9 and MLL-AF9 is
consistent with the fact that these two oncogenes have similar
effects on the proliferation and differentiation of primary human
CD34+ cells (Figures 1 and 2) and the fact that MLL and NUP98
fusions share similar clinical presentations [5,6,9,11,12,13].
Microarray data were also analyzed using the Significance
Analysis of Microarrays (SAM) [28]. The results again showed
that, unlike MLL-AF9 and NUP98-HOXA9, maximal gene
deregulation by AML1-ETO and PML-RARA occurred at the 6
h time point, with the number of deregulated genes falling
dramatically at subsequent time points (Tables S13, S14, S15, S16,
S17, S18, S19, S20, S21, S22, S23 and S24).
Early overexpression of MDM2 may contribute to the
transformation of primary human cells by AML1-ETO
Interestingly, one of the genes upregulated by AML1-ETO and
PML-RARA at 6 h but not at later time points was MDM2 as
shown by fold-change analysis (Tables S1and S4) and SAM
analysis (Tables S13 and S16). MDM2 is a known inhibitor of the
tumor suppressor p53; it acts as an E3 ligase that promotes p53
degradation through a ubiquitin-dependent pathway [29]. AML1-
ETO upregulated MDM2 by 7–9 fold in two independent
microarray experiments (Table S1). This was verified by
quantitative RT-PCR, which showed 5.7-fold upregulation
(Fig. 4A). Immunoblotting showed an increase in MDM2 protein
levels 7 h after transduction with AML1-ETO, ranging from
1.6- to 2-fold over control (p,0.05) (Fig. 4B, and 4C).
To determine whether upregulation of MDM2 plays a role in
leukemic transformation by AML1-ETO, we asked whether
MDM2 inhibition can counteract the transforming effects of
AML1-ETO. Nutlin-3, a small molecule antagonist of MDM2,
was recently developed as a potent and specific inhibitor of the
MDM2-p53 interaction leading to cell cycle arrest, apoptosis, and
growth inhibition of human tumor xenografts in nude mice
[30,31]. It was therefore important to determine whether nutlin-3
can counteract the ability of AML1-ETO to induce proliferation
and self-renewal in primary human CD34+ cells. On the other
hand, while PML-RARA also upregulated MDM2, it did not
increase cell proliferation or self-renewal (Fig. 2); therefore there is
no reliable assay to determine the effect of nutlin-3 on cell
transformation by PML-RARA.
We tested the effects of nutlin-3 on proliferation in liquid culture
and LTC-IC numbers induced by AML1-ETO in primary human
CD34+ cells. As a control, primary human CD34+ cells
transduced with either empty retrovirus or with retrovirus
expressing MLL-AF9 were similarly treated with nutlin-3. The
results show that nutlin-3 has a marked antiproliferative effect in
cells expressing AML1-ETO while it has no significant effect on
untransformed cells that express empty vector or cells transformed
by MLL-AF9, which does not induce MDM2 (Fig. 5A). Even more
remarkable, nutlin-3 abolished the ability of AML1-ETO to
increase the numbers of LTC-ICs whereas it had no significant
effect on cells transduced with empty vector or those expressing
MLL-AF9 (Fig. 5B, C). These data show a specific inhibitory effect
of nutlin-3 on the proliferation and self-renewal of cells expressing
AML1-ETO and suggest that upregulation of MDM2 may play a
significant role in cell transformation by AML1-ETO.
Discussion
There are clear differences as well as similarities in clinical
behavior, pathological findings, and response to treatment among
the different categories of AML. Here we show that these
similarities and differences among AML oncogenes can be
reflected in their transforming effects on primary human CD34+
cells in vitro; and we combine this approach with early gene
expression profiling to identify MDM2 as a possible mediator and
drug target in AML1-ETO leukemogenesis.
Studies of the in vitro leukemic transformation of primary human
hematopoietic cells by AML fusion oncogenes are not many. Yet
there has been a great deal of variability in the techniques and
conditions used to study the different oncogenes [15,16,17,
19,20,21]. Variables have included: a) Source of human cells:
cord blood versus peripheral blood mobilized CD34+ cells. b)
FACS sorting of the transduced cells versus bulk culture prior to
analysis; c) Different cytokines and/or different cytokine concen-
trations used to supplement culture media; and d) Different assays
for proliferation, self-renewal and differentiation. Not surprisingly,
the results have been difficult to compare and sometimes
contradictory. For example, our finding that AML1-ETO has
little effect on myeloid differentiation differs from recently
Figure 1. Effects of AML fusion oncogenes on the differentiation of primary human CD34+ cells. (A) Immunoblotting shows expression
of the indicated AML oncogenes in primary human CD34+ cells. (B) CFC assays of primary human CD34+ cells transduced with the indicated
oncogenes. Unmagnified plates are shown in the upper panels and representative fields of Giemsa-stained Cytospin preparations from the CFC plates
are shown in the lower panels. Differential counts are shown in Table 2. (C) Flow cytometric analysis of myeloid differentiation of cells harvested from
the CFC plates. Myeloid (CD33+) cells were gated and the level of CD11b expression was plotted on histograms in comparison to control. (D) Flow
cytometric analysis of erythroid differentiation of cells harvested from the CFC plates. Erythroid (CD235+) cells were gated and their level of CD71
expression was plotted on histograms in comparison to control.
doi:10.1371/journal.pone.0012464.g001
Table 1. CFCs colony counts.
Erythroid Myelomonocytic Mixed
Control 102.7612.7 116.0617.9 3.361.2
AML1-ETO 66.366.3* 95.764.1 2.760.5
PML-RARA 133.3614* 107.766.6 5.061.6
MLL-AF9 108.062.9 119.764.6 9.362.1
NUP98-HOXA9 120.067.5* 117.7610.4 13.364.8
*P,0.05
Colonies on CFC plates were counted at 40X magnification and classified into
three categories: erythroid, myelomonocytic, and mixed. The P value was
obtained by comparing to the control using a paired two-tailed distribution
t-test. Averages from 3 independent experiments are shown.
doi:10.1371/journal.pone.0012464.t001
AML Oncogenes in CD34+ Cells
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differentiation in vitro [16,32]. These studies differ from ours in
several respects including the use of cord blood cells, liquid as
opposed to semi-solid culture media, different cytokine conditions,
and different durations of culture. The effect of differences in
cytokine conditions are well illustrated by a study on the effects of
PML-RARA on primary human hematopoietic cells [15]. In that
study, a limited set of cytokines was used in serum-free media, and
cell numbers were monitored over a period of approximately 2
weeks. It was shown that reducing the cytokine concentration
accentuated the difference in survival and proliferation between
control cells and cells expressing PML-RARA over this time
period.
In this study we used identical conditions to compare the effects
of 4 representative oncogenes on the differentiation, proliferation,
and self-renewal of primary human CD34+ cells. The differenti-
ation data were particularly interesting: both NUP98-HOXA9
and MLL-AF9 caused a profound disruption of myeloid and
erythroid differentiation with increased numbers of erythroid cells.
On the other hand, AML1-ETO and PML-RARA had no effect
on erythroid maturation at the cellular level and only a modest
effect on myeloid maturation. It is interesting to note that NUP98
and MLL gene rearrangements are associated with myelodyspla-
sia, a condition that is often associated with erythroid hyperplasia
and abnormal erythroid maturation [33]. These data show that
the clinical similarities between NUP98 and MLL gene rear-
rangements are reflected in similar in vitro modes of transforma-
tion. One possible mechanism that may account for the similarity
between NUP98 and MLL rearrangements is the overexpression
of homeobox transcription factors, which could also explain the
poor clinical outcome of AML with NUP98 and MLL gene
rearrangements [34,35,36].
The oncogenes we tested caused long-term proliferation and
increased self-renewal of primary human CD34+ cells, with the
exception of PML-RARA. There is evidence that the ability of
PML-RARA to cause leukemia in mice is inversely proportional to
its level of expression [37]. There is also evidence that reducing the
numberandconcentrationsofcytokinescanenhancetheshort-term
proliferation of primary human hematopoietic cells expressing
PML-RARA [15]. Future experiments directed at fine-tuning of the
expression level of PML-RARA and the cytokine conditions may
produce long-term growth of primary human cells and enable the
testing ofpotentialdrug candidates;however, forthe purposesofthe
current study, uniform conditions were of primary importance in
order to compare the effects of the different oncogenes.
A few reports are available on gene expression profiling of in vitro
transformed primary human hematopoietic cells [19,20,21,23].
These were typically performed at least a few days if not weeks or
months after retroviral introduction of the oncogene. Therefore the
changes observed may reflect the particular differentiation state of
the transformed cells rather than the initial transforming events.
Several reports are available comparing the gene expression profiles
of leukemic cells from AML patients [38,39,40,41,42,43,44].
However, while the bulk of the leukemic cells consist of blasts,
proliferation of the tumor is driven by a small population of
leukemic stem cells [45]. Therefore gene expression profiling of
patient material may not reflect gene expression in leukemic stem
cells or the early events in leukemic transformation. We reasoned
that the initial effects of oncogenes are likely to confer the
proliferation advantage that leads to leukemia, and sought to
identify those early effects using nucleofection to identify deregu-
lated genes in primary human CD34+ cells within 6 h. In addition,
we used traditional retroviral transduction techniques to identify
genes deregulated at later time points. Our results confirmed some
of what was known about AML oncogenes. For example, the vast
majority of gene deregulation by AML1-ETO and PML-RARA
occurred at the 6 h time point, consistent with their known role as
direct transcriptional regulators. Further, these two oncogenes had
predominantly repressive effects on gene transcription, consistent
with their known roles as transcriptional repressors [3,27]. In
addition, our microarrays showed overexpression of homeobox
genes in primary human CD34+ cells expressing MLL-AF9,
consistent with previous results showing overexpression of these
genes in both mouse and human leukemias with MLL fusions
[46,47]. On the other hand, many of the deregulated genes we
identified have not been previously identified in molecular
signatures from patients with the corresponding oncogene
[38,39,40,41,42,43,44]. In particular, one of the genes upregulated
at the 6 h time point by AML1-ETO and PML-RARA was the p53
inhibitor MDM2. While MDM2 is known to be upregulated in
many human cancers [48], it has not been previously shown to be
upregulated in leukemic patients with either AML1-ETO or PML-
RARA [38,39,40,41,42,43,44].
The role of the p53 tumor suppressor pathway in AML1-ETO
leukemogenesis is not well understood. Leukemic cells from patients
with AML1-ETO usually have wild type p53 [49], and there is
evidence for p53 activation in leukemic cells with AML1-ETO [23].
These data raise the question of how the p53 pathway is suppressed
during AML1-ETO leukemogenesis. The p53 pathway is regulated
by an interplay between MDM2 and p14(ARF): MDM2 is an E3
Table 2. The effects of the fusion oncogenes on hematopoietic differentiation assessed by cell morphology.
Control AML1-ETO PML-RARA MLL-AF9 NUP98-HOXA9
Primitive cells % 1.160.5 6.661.6
* 3.861.7*** 10.963.1
* 9.361.5
*
Intermediate myeloid % 7.362.7 9.362.3 17.463.5
* 16.060.5
* 22.264.3
*
Mature myeloid % 63.862.6 57.762.7 48.664.7
* 21.864.4
* 12.862.3
**
Intermediate erythroid % 5.063.0 2.760.8 3.461.4 14.861.5
* 30.466.0
*
Mature erythroid % 22.863.1 23.864.2 26.562 36.761.9
* 25.065.5
Total Cells x10
6 7.560.9 7.261.1 760.6 7.561.0 11.660.5
*
*P,0.05
**P,0.01
***P=0.0507
Cells from 2 CFC plates for each experimental condition were harvested, Giemsa-stained Cytospin smears were prepared, and 500-cell differential counts were
performed. The numbers shown are averages from 3 independent experiments 6 standard deviations. The P value was obtained by comparing to control using a paired
two-tailed distribution t-test.
doi:10.1371/journal.pone.0012464.t002
AML Oncogenes in CD34+ Cells
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MDM2 and therefore stabilizes p53 [29,50,51,52]. One mechanism
by which AML1-ETO suppresses the p53 pathway is by
downregulating p14 (ARF) [53]. Our data suggest that early
upregulation of MDM2 is another possible mechanism by which
AML1-ETO overcomes the p53 tumor suppressor pathway, and
show that the MDM2 inhibitor nutlin-3 causes a specific inhibition
of the proliferation and self-renewal of cells transformed by AML1-
ETO. A possible role for nutlin-3 in the treatment of AML1-ETO
leukemias is further supported by the finding that nutlin-3 induced
apoptosis in leukemic blasts from patients with AML1-ETO
[54,55]. However, it is possible that the inhibitory effects of
nutlin-3 on cells expressing AML1-ETO may have mechanisms
other than inhibitionof MDM2. Itwould be of interestto determine
the effects of MDM2 knockdown on proliferation and LTC-IC
numbers in cells expressing AML1-ETO. MDM2 overexpression as
a mechanism of p53 inactivation has been described in several
hematopoietic and non-hematopoietic neoplasms [48]. However,
the mechanisms by which hematopoietic neoplasms upregulate
MDM2 are largely unknown, and the mechanism by which AML1-
ETO induces MDM2 expression also remains to be determined.
MDM2 is known to be induced by p53 [52], and in vitro data suggest
that the p53 pathway is activated by AML1-ETO in primary
human CD34+ cells [23]. However, this occurs as a late event
during culture secondary to accumulating DNA damage [23]; it is
therefore unlikely that the early MDM2 upregulation by AML1-
ETO is secondary to p53 activation.
MDM2 was also upregulated by PML-RARA; however, there
was no robust assay to determine whether MDM2 inhibition has
an effect on the transformation of human cells by PML-RARA
because PML-RARA did not induce a significant increase in cell
proliferation and self-renewal.
To identify additional pathways deregulated by AML onco-
genes we analyzed the gene lists generated by SAM (Tables S13,
S14, S15, S16, S17, S18, S19, S20, S21, S22, S23 and S24) using
GeneGo software. For each oncogene, a list representing the union
Figure 2. Effects of AML fusion oncogenes on the proliferation and self-renewal of primary human CD34+ cells. (A) Long-term liquid
culture of primary human CD34+ cells transduced with the indicated oncogenes. Data are representative of 3 independent experiments. (B)
Representative plates from LTC-IC assays of primary human CD34+ cells transduced with the indicated oncogenes. * Due to the much larger number
of LTC-ICs in the MLL-AF9 sample, the MLL-AF9 plate was seeded with 1/10 of the sample in order to allow the visualization of discrete colonies. Data
are representative of 3 independent experiments. (C) Average numbers of LTC-ICs per 10,000 input cells from 3 independent experiments.
doi:10.1371/journal.pone.0012464.g002
Figure 3. Microarray analysis of the effects of AML fusion oncogenes on primary human CD34+ cells. Temporal patterns of gene
deregulation by the indicated oncogenes. Primary human CD34+ cells were transduced with the indicated oncogenes by nucleofection for the 6-hour
time point and retrovirally for the 3- and 8-day time points. Cells were sorted for GFP expression and compared to empty vector controls. The
numbers shown are of genes that were up- or down-regulated by 2-fold or more in two separate experiments.
doi:10.1371/journal.pone.0012464.g003
AML Oncogenes in CD34+ Cells
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deregulated pathways based on enrichment score were identified
(Table S25). Interestingly, for all 4 oncogenes, the top 10
deregulated pathways included the TGF and WNT cytoskeletal
remodeling pathway and the epithelial-to-mesenchymal transition
(EMT) pathway. The TGF-b and WNT signaling pathways are
well known to be involved in the pathogenesis of malignancies,
including AML [56,57,58]. On the other hand, the EMT pathway
is important during development, and has a well-established role
in tumor progression and metastasis, particularly in carcinomas
[59,60], but not in hematopoietic malignancy. Our data suggest a
novel role for the EMT pathway in the pathogenesis of AML.
In summary, our data illustrate the potential of studying the
effects of AML oncogenes on primary human CD34+ cells using a
combination of early gene expression profiling with in vitro assays
of proliferation and differentiation. The former can suggest
possible drug targets, while the latter can be used as assays to
measure the effects of potential drugs. MLL and NUP98 gene
rearrangements share a poor prognosis in patients with AML and
a fairly specific set of in vitro effects on primary human CD34+
cells, most prominent among which is their profound effect on the
number and differentiation of erythroid precursors. It would be of
interest to determine whether drugs that abrogate these effects in
vitro would be useful clinically in overcoming the resistance of these
types of AML to therapy.
Materials and Methods
Plasmid Construction
The AML1-ETO cDNA, obtained from pHR’-PGK-ETO-EGFP
(kindlyprovidedbyDrs.S.D.NimerandJ.C.Mulloy)withKpnI/AgeI,
was subcloned into the KpnI/EcoRV sites of pcDNA3.1Hygro(+).
PML-RARA and MLL-AF9 cDNAs were kindly provided by Dr.
T.J. Ley and Dr. J.L. Hess, respectively. The cDNAs were subcloned
into HpaI of MSCV-IRES-GFP, and into pTracer-CMV/Bsd using
NheI/EcoRI (AML1-ETO) NotI (PML-RARA) and EcoRV (MLL-
AF9). HA-tagged NUP98-HOXA9 in MSCV-IRES-GFP and
pTracer-CMV/Bsd were previously described [20].
Retrovirus production and transduction
NUP98-HOXA9-expressing retrovirus was previously described
[20]. Other retrovirus stocks were generated by transfecting
GP293 packaging cells with 4.4 mg retroviral vector and 1.1 mg
pVSV-G expression vector using Lipofectamine Plus reagent
(Invitrogen). After 48 h, supernatant containing VSV-G-pseudo-
typed retrovirus was used to transfect PG13 packaging cells by
spinoculation with 8 mg/mL hexadimethrine bromide (Sigma-
Aldrich) to produce stable cell lines producing GaLV-pseudotyped
retrovirus. Primary human CD34+ cells from mobilized peripheral
blood of normal donors were purchased from the Fred Hutchinson
Cancer Research Center or obtained from deceased autologous
transplant patients from the Bone Marrow Transplant Laboratory
at Northwestern Memorial Hospital after Institutional Review
Board approval. For each experiment all 4 oncogenes and controls
were tested using the same cell source. Cells were pre-activated
and transduced with retrovirus as previously described [20]. After
48 h, GFP positive cells were sorted using a MoFlo high-speed
sorter (Dako).
Nucleofection
Preactivated primary human CD34+ cells were nucleofected
with pTracer-CMV/Bsd constructs expressing the fusion proteins
Figure 4. MDM2 overexpression in primary human CD34+ cells transduced with AML1-ETO. (A) Quantitative RT-PCR confirms early
overexpression of MDM2 RNA by CD34+ cells transduced with AML1-ETO. Fold change shown is the average of 3 independent experiments. (B)
Immunoblotting shows increased MDM2 protein levels in cells transduced with AML1-ETO. (C) MDM2 protein was quantified by using the ChemiDoc
XRS imaging system (Bio-Rad) with Quantity One 1-D software and fold change over control was calculated. Fold change shown is the average of 3
independent experiments.
doi:10.1371/journal.pone.0012464.g004
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5/
mL in complete cytokine medium [20] for 3.5 h. GFP+ cells were
sorted using MoFlo sorter and cultured at 10
5/mL in complete
cytokine medium for 2.5 h before RNA isolation.
Immunolotting
Total cell lysates were checked for protein expression by
immunoblotting using: anti-HA (12CA5) (Roche) for NUP98-
HOX9; anti-AML-1 (Ab-2) (EMD Chemicals) for AML1-ETO;
anti-MLL/HRX clone N4.4, (Millipore) for MLL-AF9; anti
RARA (C-20) for PML-RARA and anti-MDM2 (N-20) for
MDM2 (Santa Cruz Biotechnology). MDM2 protein was
quantified using the ChemiDoc XRS imaging system (Bio-Rad)
with Quantity One 1-D software and fold change over control was
calculated.
Analysis of differentiation
Colony-forming cell (CFC) assays were performed as previously
described [20]. Briefly, 1000 sorted cells were seeded into each of
two duplicate plates; after 14 days, colonies were counted and cells
were collected. Giemsa-stained Cytospin slides were prepared and
500-cell differential counts were performed using an Olympus
BX51 microscope. Cells were divided into five categories:
primitive cells include blasts and promyelocytes; intermediate
myeloid cells include myelocytes/metamyelocytes; mature myeloid
cells include bands, segmented neutrophils, monocytes, and
macrophages; intermediate erythroid cells include cells with
intermediate hemoglobinization; and mature erythroid cells
include cells with full hemoglobinization. Photomicrographs were
taken with an Olympus DP71 camera with a 60X oil objective.
Flow cytometry was performed on a FACSCalibur flow cytometer
(BD Biosciences), and analyzed using FlowJO v7.5 (Tree Star)
software. Antibodies used were: CD11b (phycoerythrin-conjugat-
ed clone D12); CD235a (allophycocyanin-conjugated clone GA-
R2) and CD71 (phycoerythrin-conjugated clone M-A712) from
BD; CD33 (allophycocyanin-conjugated clone D3HL60.251) and
CD45 (phycoerythrin-Cy7-conjugated clone J.33) from Beckman
Coulter.
Liquid culture, long-term culture-initiating cell (LTC-IC)
assays, and nutlin-3 treatment
Liquid culture was carried out in Iscove’s modified Dulbecco’s
medium (IMDM) containing 20% FBS, 100 ng/ml Fms-related
tyrosine kinase 3 (Flt 3)-ligand, 20 ng/ml granulocyte/macro-
phage colony-stimulating factor (GM-CSF), 100 ng/ml stem cell
factor (SCF), 100 ng/ml thrombopoietin (TPO), 50 ng/ml IL-3,
100 ng/ml IL-6 (all cytokines were from Peprotech, Rocky Hill,
NJ, USA), 2 mM L-glutamine, and 100 units/ml penicillin/
streptomycin as previously described [20]. LTC-IC assays were
performed as described [20] except that cells transduced with
MLL-AF9 were seeded at 1/10 cell density in methylcellulose for
LTC-IC due to their high number of LTC-ICs. Nutlin-3,
(Cayman Chemical, Ann Arbor, Michigan, USA), was dissolved
in DMSO at 10 mM and stored at 220uC. Cells in long-term
liquid culture were exposed to 1 mM nutlin-3 or vehicle during
each round of feeding. LTC-IC plates were exposed to 2 mM
nutlin-3 or vehicle weekly.
Quantitative real-time PCR
Template cDNA was synthesized using SuperScript III First-
Strand Synthesis System (Invitrogen). Real-time PCR was
performed in triplicate using the StepOne Plus Real-Time PCR
System and analyzed with the StepOne software version 2
(Applied Biosystems) with the following two primer pairs:
For MDM2: 59GCCTTAGTGAAGAAGGACAAG39
59TCCCTTTATCTTCAGGAAGCC39
For GAPDH: 59GGACCTGACCTGCCG39
59TAGCCCAGGATGCCCTTGAG39.
The expression level of MDM2 was normalized to GAPDH.
Microarray analysis of primary human CD34+ cells
GFP-sorted cells were collected and snap-frozen 6 h after
nucleofection, or 3 and 8 days after retroviral transduction.
Total RNA isolated using the RNeasy mini kit (Qiagen) was
submitted to the Siteman Cancer Center Laboratory for Clinical
Genomics. Target was prepared using linear amplification
protocol for the 6 h time point and standard protocol for the
3 and 8 day time points and hybridized to Affymetrix HG-U133
Plus 2.0 GeneChip arrays according to manufacturer’s instruc-
tions. The experiment was performed two independent times.
Microarray data were merged with updated gene annotation
data using DecisionSite for Functional Genomics software
(Spotfire) 9.1.1. Probesets scored as absent across all chips were
filtered out. Fold change was calculated by dividing the absolute
signal intensity from oncogene samples by that of the control.
P r o b e s e t ss c o r e da si n c r e a s i n ga n da b s e n ti nt h en u m e r a t o r ,o r
decreasing and absent in the denominator were filtered out.
Probesets induced or repressed by twofold or greater relative to
control in both replicates were considered differentially
expressed. Data filtering was done using Spotfire 9.1.1. For
Significance Analysis for Microarrays (SAM) [28], the absolute
signal intensities of the genes induced by each oncogene and the
control at each time point were first filtered as described above.
The log base 2 of the absolute signal intensities was computed,
and assembled into a single tab-delimited file for each
comparison. SAM was run with the maximum number of
unique permutations available using a two-class unpaired
setting, and delta values were chosen to give a median false
discovery rate (FDR) of 10% or lower, with the exception of the
PML-RARA 3-day time point where the lowest possible FDR
was 10.3%. All other parameters were set to the defaults. An
arbitrary 2-fold cutoff threshold was then applied to the lists of
significant genes from the SAM analysis. The resulting list of
statistically significant probes was merged with the updated gene
annotation data for each probe set on the array using Spotfire
9.1.1. For each oncogene, a union list of deregulated genes at all
time points was generated and analyzed using MetaCore
TM
version 6.3 build 25177 (GeneGo, Inc.). The top 10 significant
pathways at an FDR threshold of 0.05 were chosen based on
enrichment score for each of the oncogenes.
Figure 5. Nutlin-3 specifically inhibits the proliferation and self-renewal of primary human CD34+ cells expressing AML1-ETO. (A)
Liquid culture of primary human CD34+ cells transduced with empty vector or vector expressing AML1-ETO or MLL-AF9, in the presence or absence
of nutlin-3. Data are representative of 3 independent experiments. (B) LTC-IC assays of primary human CD34+ cells transduced with empty vector or
vector expressing AML1-ETO or MLL-AF9, in the presence or absence of nutlin-3. Shown are representative LTC-IC plates from 3 independent
experiments. * Due to the much larger number of LTC-ICs in the MLL-AF9 sample, the MLL-AF9 plates were seeded with only 1/10 of the sample in
order to allow the visualization of discrete colonies. (C) Average numbers of LTC-ICs as percentage of vehicle sample from 3 separate experiments are
shown.
doi:10.1371/journal.pone.0012464.g005
AML Oncogenes in CD34+ Cells
PLoS ONE | www.plosone.org 10 August 2010 | Volume 5 | Issue 8 | e12464Supporting Information
Table S1 Genes deregulated by AML1-ETO 6 hours after
transfection. Primary human CD34+ cells were nucleofected with
either control pTracer-CMV/Bsd vector or vector expressing
AML1-ETO and sorted for GFP positivity. Total RNA was
extracted 6 h after nucleofection and subjected to microarray
analysis. Genes that showed up- or down-regulation by 2 fold or
more in comparison to the control in 2 independent experiments
(Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s001 (0.36 MB
PDF)
Table S2 Genes deregulated by AML1-ETO 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing AML1-ETO and sorted for GFP positivity. Total RNA
was extracted 3 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation
by 2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s002 (0.10 MB
PDF)
Table S3 Genes deregulated by AML1-ETO 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing AML1-ETO and sorted for GFP positivity. Total RNA
was extracted 8 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation
by 2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s003 (0.08 MB
PDF)
Table S4 Genes deregulated by PML-RARA 6 h after trans-
fection. Primary human CD34+ cells were nucleofected with
either control pTracer-CMV/Bsd vector or vector expressing
PML-RARA and sorted for GFP positivity. Total RNA was
extracted 6 h after nucleofection and subjected to microarray
analysis. Genes that showed up- or down-regulation by 2 fold or
more in comparison to the control in 2 independent experiments
(Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s004 (0.18 MB
PDF)
Table S5 Genes deregulated by PML-RARA 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing PML-RARA and sorted for GFP positivity. Total RNA
was extracted 3 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation
by 2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s005 (0.08 MB
PDF)
Table S6 Genes deregulated by PML-RARA 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing PML-RARA and sorted for GFP positivity. Total RNA
was extracted 8 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation
by 2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s006 (0.08 MB
PDF)
Table S7 Genes deregulated by MLL-AF9 6 h after transfec-
tion. Primary human CD34+ cells were nucleofected with either
control pTracer-CMV/Bsd vector or vector expressing MLL-AF9
and sorted for GFP positivity. Total RNA was extracted 6 h after
nucleofection and subjected to microarray analysis. Genes that
showed up- or down-regulation by 2 fold or more in comparison to
the control in 2 independent experiments (Exp.1 and Exp.2) were
considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s007 (0.08 MB
PDF)
Table S8 Genes deregulated by MLL-AF9 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing MLL-AF9 and sorted for GFP positivity. Total RNA
was extracted 3 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation
by 2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s008 (0.11 MB
PDF)
Table S9 Genes deregulated by MLL-AF9 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing MLL-AF9 and sorted for GFP positivity. Total RNA
was extracted 8 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation
by 2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s009 (0.10 MB
PDF)
Table S10 Genes deregulated by NUP98-HOXA9 6 h after
transfection. Primary human CD34+ cells were nucleofected with
either control pTracer-CMV/Bsd vector or vector expressing
NUP98-HOXA9 and sorted for GFP positivity. Total RNA was
extracted 6 h after nucleofection and subjected to microarray
analysis. Genes that showed up- or down-regulation by 2 fold or
more in comparison to the control in 2 independent experiments
(Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s010 (0.11 MB
PDF)
Table S11 Genes deregulated by NUP98-HOXA9 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or
vector expressing NUP98-HOXA9 and sorted for GFP positivity.
Total RNA was extracted 3 days after transduction and subjected
to microarray analysis. Genes that showed up- or down-
regulation by 2 fold or more in comparison to the control in 2
independent experiments (Exp.1 and Exp.2) were considered
deregulated.
Found at: doi:10.1371/journal.pone.0012464.s011 (0.05 MB
PDF)
Table S12 Genes deregulated by NUP98-HOXA9 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing NUP98-HOXA9 and sorted for GFP positivity. Total
RNA was extracted 8 days after transduction and subjected to
microarray analysis. Genes that showed up- or down-regulation by
2 fold or more in comparison to the control in 2 independent
experiments (Exp.1 and Exp.2) were considered deregulated.
Found at: doi:10.1371/journal.pone.0012464.s012 (0.11 MB
PDF)
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transfection. Primary human CD34+ cells were nucleofected with
either control pTracer-CMV/Bsd vector or vector expressing
AML1-ETO and sorted for GFP positivity. Total RNA was
extracted 6 h after nucleofection and subjected to microarray
analysis. Microarray data were analyzed by SAM as described in
Materials and Methods. Significantly deregulated genes are listed
and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s013 (0.79 MB
PDF)
Table S14 Genes deregulated by AML1-ETO 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or
vector expressing AML1-ETO and sorted for GFP positivity.
Total RNA was extracted 3 days after transduction and
subjected to microarray analysis. Microarray data were
analyzed by SAM as described in Materials and Methods.
Significantly deregulated genes are listed and the false discovery
rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s014 (0.06 MB
PDF)
Table S15 Genes deregulated by AML1-ETO 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing AML1-ETO and sorted for GFP positivity. Total RNA
was extracted 8 days after transduction and subjected to
microarray analysis. Microarray data were analyzed by SAM as
described in Materials and Methods. Significantly deregulated
genes are listed and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s015 (0.15 MB
PDF)
Table S16 Genes deregulated by PML-RARA 6 h after
transfection. Primary human CD34+ cells were nucleofected with
either control pTracer-CMV/Bsd vector or vector expressing
PML-RARA and sorted for GFP positivity. Total RNA was
extracted 6 h after nucleofection and subjected to microarray
analysis. Microarray data were analyzed by SAM as described in
Materials and Methods. Significantly deregulated genes are listed
and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s016 (0.40 MB
PDF)
Table S17 Genes deregulated by PML-RARA 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing PML-RARA and sorted for GFP positivity. Total RNA
was extracted 3 days after transduction and subjected to
microarray analysis. Microarray data were analyzed by SAM as
described in Materials and Methods. Significantly deregulated
genes are listed and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s017 (0.14 MB
PDF)
Table S18 Genes deregulated by PML-RARA 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing PML-RARA and sorted for GFP positivity. Total RNA
was extracted 8 days after transduction and subjected to
microarray analysis. Microarray data were analyzed by SAM as
described in Materials and Methods. Significantly deregulated
genes are listed and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s018 (0.19 MB
PDF)
Table S19 Genes deregulated by MLL-AF9 6 h after transfec-
tion. Primary human CD34+ cells were nucleofected with either
control pTracer-CMV/Bsd vector or vector expressing MLL-AF9
and sorted for GFP positivity. Total RNA was extracted 6 h after
nucleofection and subjected to microarray analysis. Microarray
data were analyzed by SAM as described in Materials and
Methods. Significantly deregulated genes are listed and the false
discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s019 (0.26 MB
PDF)
Table S20 Genes deregulated by MLL-AF9 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing MLL-AF9 and sorted for GFP positivity. Total RNA
was extracted 3 days after transduction and subjected to
microarray analysis. Microarray data were analyzed by SAM as
described in Materials and Methods. Significantly deregulated
genes are listed and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s020 (0.35 MB
PDF)
Table S21 Genes deregulated by MLL-AF9 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing MLL-AF9 and sorted for GFP positivity. Total RNA
was extracted 8 days after transduction and subjected to
microarray analysis. Microarray data were analyzed by SAM as
described in Materials and Methods. Significantly deregulated
genes are listed and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s021 (0.27 MB
PDF)
Table S22 Genes deregulated by NUP98-HOXA9 6 h after
transfection. Primary human CD34+ cells were nucleofected with
either control pTracer-CMV/Bsd vector or vector expressing
NUP98-HOXA9 and sorted for GFP positivity. Total RNA was
extracted 6 h after nucleofection and subjected to microarray
analysis. Microarray data were analyzed by SAM as described in
Materials and Methods. Significantly deregulated genes are listed
and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s022 (0.30 MB
PDF)
Table S23 Genes deregulated by NUP98-HOXA9 3 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or
vector expressing NUP98-HOXA9 and sorted for GFP
positivity. Total RNA was extracted 3 days after transduction
and subjected to microarray analysis. Microarray data were
analyzed by SAM as described in Materials and Methods.
Significantly deregulated genes are listed and the false discovery
rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s023 (0.21 MB
PDF)
Table S24 Genes deregulated by NUP98-HOXA9 8 days after
transduction. Primary human CD34+ cells were retrovirally
transduced with either control MSCV-IRES-GFP vector or vector
expressing NUP98-HOXA9 and sorted for GFP positivity. Total
RNA was extracted 8 days after transduction and subjected to
microarray analysis. Microarray data were analyzed by SAM as
described in Materials and Methods. Significantly deregulated
genes are listed and the false discovery rate (FDR) is shown.
Found at: doi:10.1371/journal.pone.0012464.s024 (0.25 MB
PDF)
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were generated from the lists shown in Tables S13 - S24 and
subjected to GeneGo analysis as described in Materials and
Methods. The top 10 enriched pathways for each oncogene are
shown along with the corresponding p-values.
Found at: doi:10.1371/journal.pone.0012464.s025 (0.05 MB
PDF)
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